Literature DB >> 21103177

Ethical issues in diagnosing and treating Alzheimer disease.

Edmund G Howe1.   

Abstract

Many unique ethical issues arise when diagnosing and treating Alzheimer disease (AD). This article discusses several core ethical dilemmas that arise for psychiatrists during different stages of AD, focusing particularly on areas of consensus and controversy. Issues addressed include screening, genetic testing, and discussions of advance directives during early stages; telling soft and even outright lies during middle and late stages; and withholding life-preserving interventions during the last stage of AD when death is imminent. While there is overwhelming ethical consensus that psychiatrists should be fully honest and respect patient autonomy as much as possible during the early stages of disease, there is more controversy regarding the extent to which psychiatrists should do this during the later stages of disease. Possible, optimal approaches to resolving these ethical issues are presented.

Entities:  

Keywords:  Alzheimers; dementia; ethics

Year:  2006        PMID: 21103177      PMCID: PMC2990623     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  44 in total

Review 1.  Management of severe Alzheimer's disease and end-of-life issues.

Authors:  L Volicer
Journal:  Clin Geriatr Med       Date:  2001-05       Impact factor: 3.076

2.  Alzheimer's disease: to tell or not to tell.

Authors:  Ronald C Hamdy
Journal:  South Med J       Date:  2004-01       Impact factor: 0.954

3.  End-of-life care for persons with Alzheimer's disease.

Authors:  Kye Y Kim; Paul A Yeaman; Reba L Keene
Journal:  Psychiatr Serv       Date:  2005-02       Impact factor: 3.084

4.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

5.  Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.

Authors:  Kathleen N Franco; Barbara Messinger-Rapport
Journal:  J Am Med Dir Assoc       Date:  2006-02-07       Impact factor: 4.669

6.  Major and minor depression in Alzheimer's disease: prevalence and impact.

Authors:  C G Lyketsos; C Steele; L Baker; E Galik; S Kopunek; M Steinberg; A Warren
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1997       Impact factor: 2.198

7.  Suicide in two patients with a diagnosis of probable Alzheimer disease.

Authors:  S H Ferris; G T Hofeldt; G Carbone; P Masciandaro; W M Troetel; B P Imbimbo
Journal:  Alzheimer Dis Assoc Disord       Date:  1999 Apr-Jun       Impact factor: 2.703

8.  Clinical predictors of aggressive behaviour in Alzheimer's disease.

Authors:  N Gormley; M R Rizwan; S Lovestone
Journal:  Int J Geriatr Psychiatry       Date:  1998-02       Impact factor: 3.485

9.  The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.

Authors:  C Holmes; D Wilkinson; C Dean; S Vethanayagam; S Olivieri; A Langley; N D Pandita-Gunawardena; F Hogg; C Clare; J Damms
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

10.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Authors:  Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

View more
  2 in total

Review 1.  Could Early Identification of Changes in Olfactory Function Be an Indicator of Preclinical Neurodegenerative Disease? A Systematic Review.

Authors:  Rikki L Winchester; Kathy Martyn
Journal:  Neurol Ther       Date:  2020-06-11

Review 2.  Primary Prevention of Dementia: An Ethical Review.

Authors:  Dorothee Horstkötter; Kay Deckers; Sebastian Köhler
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.